Quest Diagnostics (NYSE: DGX) — Perfil da empresa, notícias e dados financeiros
Quest Diagnostics provides diagnostic testing and information services, aiming to improve health outcomes through innovative testing solutions.
Quest Diagnostics
Quest Diagnostics is a provider of diagnostic testing, information, and services. Operating a network of patient service centers, regional laboratories, and specialized testing facilities, the company serves patients, healthcare professionals, hospital systems, health plans, employers, and life sciences organizations. Its diagnostic offerings encompass routine clinical testing, anatomical pathology, esoteric testing, gene-based diagnostics, and workforce drug screening. Quest Diagnostics also offers lab management tools, clinical trial support, direct-to-consumer lab testing, and health data analytics services designed to support clinical decision-making, population health management, and patient care outcomes.
Resumo
Operações
Produtos e/ou serviços de Quest Diagnostics
- Routine Clinical Diagnostic Testing: Providing general clinical laboratory services, including blood chemistry, hematology, urinalysis, immunochemistry, and endocrinology panels across over 2,000 patient service centers and regional processing laboratories for individual patients and physician offices.
- Gene-Based and Esoteric Diagnostics: Delivering advanced diagnostic testing services in specialty medical areas such as oncology, human genetics, neurology, infectious diseases, and immunology to aid in early disease detection, biomarker discovery, and targeted therapy selection.
- Hospital and Health System Lab Solutions: Supplying comprehensive laboratory management, outreach partnerships, professional consultation, and reference testing services to assist hospitals, health networks, and academic medical centers in optimizing operational efficiency and diagnostic performance.
- Direct-to-Consumer Lab Testing: Offering an online marketplace platform that enables consumers to select, purchase, and access more than 150 laboratory tests directly without requiring a prior physician visit, with sample collection at patient service centers.
- Workforce Drug Screening and Population Health: Providing employer-focused healthcare services including workplace drug and alcohol testing programs, clinical drug monitoring, occupational health screenings, and preventative population health management tools to assess employee health risks and workplace safety.
- Life Sciences and Clinical Trial Support: Delivering laboratory services, assay development, biomarker education, and clinical research trial support for pharmaceutical, biotechnology, medical device, and contract research organizations across global development programs.
equipe executiva do Quest Diagnostics
- James E. DavisChairman, CEO & President
- Sam A. SamadExecutive VP & CFO
- Michael E. PrevoznikSenior VP & General Counsel
- Catherine T. DohertyExecutive Vice President of Regional Businesses
- Karthik KuppusamySenior Vice President of Clinical Solutions
- Michael J. DeppeSenior VP, Corporate Controller & Chief Accounting Officer
- Murali BalakumarSenior VP and Chief Information & Digital Officer
- Damini ChokshiVice President of Investor Relations
- Kristin Lee WallaceSenior VP & Chief Compliance Officer
- Garry ClarkSenior VP and Chief Marketing & Communications Officer
Histórico de dividendos
Dividendos por ação pagos pela Quest Diagnostics, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $3.3800 |
| FY2025 | — | — | — | $3.1500 |
| FY2024 | — | — | — | $2.9600 |
| FY2023 | — | — | — | $2.7900 |
| FY2022 | — | — | — | $3.2600 |
Principais indicadores financeiros
Resultados divulgados pela Quest Diagnostics, em USD.
- Cap. de mercado
- 26,8 bi
- Receita (TTM)
- 11,8 bi
- P/L
- 24.1
- LPA (diluído, TTM)
- 10.1
- Dividend yield
- 1.4%
- Margem de lucro
- 9.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 11 bi | 1,6 bi | 992 mi | |
| 9,9 bi | 1,3 bi | 871 mi | |
| 9,3 bi | 1,3 bi | 854 mi | |
| 9,9 bi | 1,4 bi | 946 mi |